Confined or spread disease-Spread beyond the prostate gland - Page 2 of 10 Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread beyond the prostate gland Posts on Medivizor

Evaluating the impact on quality of life of giving enzulatumide in combination with hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the impact on quality of life of giving enzulatumide in combination with hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

Posted by on Dec 6, 2020 in Prostate cancer | 0 comments

In a nutshell This study investigated the quality of life after treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) with enzalutamide (Xtandi) in combination with hormone therapy. The study found that enzalutamide + hormone therapy improved the quality of life of patients, compared to hormone therapy...

Read More

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Does giving radiotherapy to metastatic sites and the prostate tumor improve the outcomes of patients with prostate cancer and few metastases?

Posted by on Nov 25, 2020 in Prostate cancer | 0 comments

In a nutshell This study aims to evaluate if giving radiotherapy to both the areas the tumor has spread (metastases), along with the prostate tumor, will improve the survival of patients with prostate cancer (PC) and few metastases (oligometastatic disease). This study suggested that this treatment could benefit patients with PC and few...

Read More

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Ipilimumab and radiotherapy improves survival in patients with metastatic castration-resistant prostate cancer

Posted by on Sep 30, 2020 in Prostate cancer | 0 comments

In a nutshell This trial was carried out to examine the effectiveness of radiotherapy followed by treatment with ipilimumab (Yervoy) in men with metastatic castrate-resistant prostate cancer  (mCRPC). The trial found that this treatment led to higher survival in these patients compared to radiotherapy followed by placebo. Some...

Read More

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

The effects of bipolar androgen therapy in men with metastatic castration resistant prostate cancer

Posted by on Jul 19, 2020 in Prostate cancer | 0 comments

In a nutshell The study evaluated outcomes of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) who were continuing drugs targeting androgen receptors (AR). The authors found that BAT was clinically effective in such patients. Some background BAT refers to sequential injections with testosterone in men...

Read More

The use of relugolix in addition to radiotherapy in patients with prostate cancer

The use of relugolix in addition to radiotherapy in patients with prostate cancer

Posted by on May 2, 2020 in Prostate cancer | 0 comments

In a nutshell The study investigated the use of relugolix (Relumina), a hormonal therapy drug, in addition to radiotherapy (RT), in managing prostate cancer. The study found that relugolix was effective in reducing androgen (male sex hormones such as testosterone) levels and well tolerated in these patients. Some background Prostate...

Read More

Evaluating docetaxel plus hormone therapy for the treatment of metastatic prostate cancer

Evaluating docetaxel plus hormone therapy for the treatment of metastatic prostate cancer

Posted by on Nov 3, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of docetaxel (Taxotere) plus hormone therapy for patients with metastatic prostate cancer (cancer that spread outside the prostate). This study found that this treatment combination improved survival for these patients, regardless of tumor burden. Some background One treatment for...

Read More

Evaluating the overall survival in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Evaluating the overall survival in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide

Posted by on Oct 27, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated the effect of apalutamide (Erleada) on survival in patients with castrate-resistant prostate cancer (CRPC). This study found that apalutamide had a positive effect on the survival of these patients. Some background One treatment option for patients with prostate cancer is androgen deprivation therapy...

Read More

Looking for patients with advanced prostate cancer to test a new treatment strategy

Posted by on Oct 24, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 2 study will investigate cryosurgical freezing (CF) and intratumoral combination immunotherapy (ITI) in advanced prostate cancer (PC). The main outcome will be the reduction in prostate specific antigen (PSA). This trial is recruiting in California and Michigan, US. The details Metastatic prostate cancer (PC) is an...

Read More

Can apalutamide improve outcomes for patients with metastatic, castration-sensitive prostate cancer?

Can apalutamide improve outcomes for patients with metastatic, castration-sensitive prostate cancer?

Posted by on Oct 22, 2019 in Prostate cancer | 0 comments

In a nutshell This study investigated whether adding apalutamide (erleada) to androgen-deprivation therapy (ADT) would improve survival in patients with prostate cancer. The authors concluded that adding apalutamide to ADT improved outcomes for these patients. Some background Androgen deprivation therapy (ADT) is the standard treatment for patients...

Read More

What are the outcomes of sipuleucel-T treatment for patients with metastatic castration-resistant prostate cancer?

What are the outcomes of sipuleucel-T treatment for patients with metastatic castration-resistant prostate cancer?

Posted by on Oct 1, 2019 in Prostate cancer | 0 comments

In a nutshell This study evaluated the safety and effectiveness of sipuleucel-T (Provenge) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). The authors found that the average survival after sipuleucel-T treatment was 30.7 months and that 13.7% of patients experienced side effects. Some background...

Read More

Searching for patients with advanced prostate cancer to test an experimental medication

Posted by on Sep 30, 2019 in Prostate cancer | 0 comments

In a nutshell This phase 2 study will investigate the safety and effectiveness of AZD4635 in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The main outcome will be the objective response rate (ORR) and prostate-specific antigen (PSA; a marker of prostate cancer) response. This trial is recruiting in multiple...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor